Leah Kuntz

5 days ago | psychiatrictimes.com | Leah Kuntz

Psychiatric Times is committed to promoting diversity, equity, and inclusion to improve patient outcomes in psychiatry. The publication encourages professionals to share insights on addressing diversity, using cultural psychotherapy, and offering practice tips. Practitioners are urged to engage effectively with patients from diverse backgrounds and share relevant experiences.

1 week ago | psychiatrictimes.com | Leah Kuntz

CONFERENCE REPORTERThis year's American Psychiatric Association (APA) Annual Meeting passed by in a blur. Just in case you missed any conference coverage, here is a recap of the top insights we learned from leaders in the field of psychiatry. At this year's meeting...

1 week ago | psychiatrictimes.com | Leah Kuntz

Take a look at this month’s developments in the psychiatric treatment pipeline. We compiled a recap of the latest news here, just in case you missed any of the updates. FDA Filing Fee Waiver for New Drug Application of NRX-100 for Suicidal DepressionNRx Pharmaceuticals received a US Food and Drug Administration (FDA) filing fee waiver for NRX-100, a preservative-free ketamine for suicidal depression.

1 week ago | psychiatrictimes.com | Leah Kuntz

CONFERENCE REPORTERIn a recent study, investigators compared rates of somnolence/sedation with dopamine partial agonists vs D2 receptor antagonists in the adjunctive treatment of major depressive disorder (MDD) and the treatment of acute schizophrenia.

1 week ago | psychiatrictimes.com | Leah Kuntz

Neurocrine Biosciences recently shared data from the phase 2 study of NBI-1117568 in adults with schizophrenia, which showed a significant improvement in symptoms and overall severity and highlighted new data on the safety and tolerability of the treatment. NBI-1117568 is the first and only investigational oral muscarinic M4 selective orthosteric agonist in clinical development as a potential treatment for schizophrenia.